Article
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
EBioMedicine - 1 Apr 2017
Rhee Soo-Yon, Varghese Vici, Holmes Susan P, Van Zyl Gert U, Steegen Kim, Boyd Mark A, Cooper David A, Nsanzimana Sabin, Saravanan Shanmugam, Charpentier Charlotte, de Oliveira Tulio, Etiebet Mary-Ann A, Garcia Federico, Goedhals Dominique, Gomes Perpetua, Günthard Huldrych F, Hamers Raph L, Hoffmann Christopher J, Hunt Gillian, Jiamsakul Awachana, Kaleebu Pontiano, Kanki Phyllis, Kantor Rami, Kerschberger Bernhard, Marconi Vincent C, D'amour Ndahimana Jean, Ndembi Nicaise, Ngo-Giang-Huong Nicole, Rokx Casper, Santoro Maria M, Schapiro Jonathan M, Schmidt Daniel, Seu Lillian, Sigaloff Kim C E, Sirivichayakul Sunee, Skhosana Lindiwe, Sunpath Henry, Tang Michele, Yang Chunfu, Carmona Sergio, Gupta Ravindra K, Shafer Robert W
Abstract excerpt
Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse transcriptase (RT) mutations selected in individuals with VF on such a regimen is not known. To identify TDF regimen-associated mutations (TRAMs), we compared the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.